Implementation and evaluation of a patient action plan for patients with atopic dermatitis

Abstract Background Management and treatment of atopic dermatitis (AD) are complex and therefore bear the risk of therapeutic failure. Individualised patient action plans for patients and for caregivers have been shown to improve AD management, eczema monitoring and therapy adherence. Little is known about the use of patient action plans in the adult setting. Objectives This project aimed at implementing a patient action plan to improve eczema management and evaluating its effects on disease severity and patient‐related outcomes. Methods This quality improvement project had a pretest–posttest design and evaluated AD severity and patient‐related outcomes after implementing a patient action plan. A convenience sample of 20 adult patients with AD was included. Socio‐demographic, diagnostic and clinical variables were collected from the electronic health records. Trained staff assessed AD severity using SCORing Atopic Dermatitis (SCORAD) and person‐centred dermatology self‐care index (PeDeSI‐G) pre as well as 1‐month postintervention. Patients completed dermatology life quality index (DLQI) and patient benefit index (PBI). For comparison of SCORAD, DLQI, PeDeSI‐G, paired t ‐test was applied. PBI was presented using descriptive statistics. Results Upon intervention, a significant decrease of disease severity ( p < 0.0001), in parallel with a significant decrease of DLQI ( p < 0.001) and PeDeSI‐G ( p < 0.0001) was observed. A PBI ≥ 1 was reached in 95% of participants (mean 2.73; SD 0.9). Conclusions Our findings confirm the importance of providing patient action plans to AD patients to achieve best treatment results. Based on our experience, we plan to modify the action plan by including both topical and systemic therapies, and to translate it into several languages.

Authors

Institutions

Publication Details

Journal
JEADV Clinical Practice
Published
2024-08-21
DOI
https://doi.org/10.1002/jvc2.531
Primary Topic
Dermatology and Skin Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Implementation and evaluation of a patient action plan for patients with atopic dermatitis

Christoph von Dach, Susanne Radonjic‐Hoesli, Dagmar Simon, Kathrin Thormann et al.
JEADV Clinical Practice
Dermatology and Skin Diseases
article

Implementation and evaluation of a patient action plan for patients with atopic dermatitis

Christoph von Dach, Susanne Radonjic‐Hoesli, Dagmar Simon, Kathrin Thormann, Lori Lupe
article en

Abstract

Abstract Background Management and treatment of atopic dermatitis (AD) are complex and therefore bear the risk of therapeutic failure. Individualised patient action plans for patients and for caregivers have been shown to improve AD management, eczema monitoring and therapy adherence. Little is known about the use of patient action plans in the adult setting. Objectives This project aimed at implementing a patient action plan to improve eczema management and evaluating its effects on disease severity and patient‐related outcomes. Methods This quality improvement project had a pretest–posttest design and evaluated AD severity and patient‐related outcomes after implementing a patient action plan. A convenience sample of 20 adult patients with AD was included. Socio‐demographic, diagnostic and clinical variables were collected from the electronic health records. Trained staff assessed AD severity using SCORing Atopic Dermatitis (SCORAD) and person‐centred dermatology self‐care index (PeDeSI‐G) pre as well as 1‐month postintervention. Patients completed dermatology life quality index (DLQI) and patient benefit index (PBI). For comparison of SCORAD, DLQI, PeDeSI‐G, paired t ‐test was applied. PBI was presented using descriptive statistics. Results Upon intervention, a significant decrease of disease severity ( p < 0.0001), in parallel with a significant decrease of DLQI ( p < 0.001) and PeDeSI‐G ( p < 0.0001) was observed. A PBI ≥ 1 was reached in 95% of participants (mean 2.73; SD 0.9). Conclusions Our findings confirm the importance of providing patient action plans to AD patients to achieve best treatment results. Based on our experience, we plan to modify the action plan by including both topical and systemic therapies, and to translate it into several languages.

JEADV Clinical PracticeVol. 4(1)
University of Bern (CH), Bern University of Applied Sciences (CH), University of North Carolina at Greensboro (US), University Hospital of Bern (CH)
Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Galderma, Sanofi Genzyme
Openalex Percentile: Top 73%
Dermatology and Skin Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.